TcpO2, arterial blood flow and lactate/pyruvate modifications induced by a single dose of naftidrofuryl IV during stage III lower-limb arteriopathies

A single dose of 600 mg of naftidrofuryl perfused IV during three hours in 12 stage III arteriopathic patients did not modify the average blood flow at the calf but did significantly increase transcutaneous oxygen pressure (33 vs 52 mmHg) and also improved lactates (1.44 vs 0.88 mmol/liter), pyruvat...

Full description

Saved in:
Bibliographic Details
Published in:Angiology 1986-09, Vol.37 (9), p.647-653
Main Authors: POINTEL, J. P, THOMAS, C, MOSNIER, M, PERCEBOIS, G, DEBRY, G
Format: Article
Language:English
Subjects:
Aged
Arterial Occlusive Diseases - blood
Arterial Occlusive Diseases - drug therapy
Arterial Occlusive Diseases - physiopathology
Biological and medical sciences
Blood Gas Monitoring, Transcutaneous
Cardiovascular system
Female
Furans - therapeutic use
Humans
Lactates - blood
Leg - blood supply
Male
Medical sciences
Middle Aged
Nafronyl - therapeutic use
Oxygen - blood
Pharmacology. Drug treatments
Pyruvates - blood
Regional Blood Flow - drug effects
Vasodilator Agents - therapeutic use
Vasodilator agents. Cerebral vasodilators
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A single dose of 600 mg of naftidrofuryl perfused IV during three hours in 12 stage III arteriopathic patients did not modify the average blood flow at the calf but did significantly increase transcutaneous oxygen pressure (33 vs 52 mmHg) and also improved lactates (1.44 vs 0.88 mmol/liter), pyruvate (59 vs 79 mumol/liter), and lactates-pyruvates ratio (33.48 vs 20.92).
ISSN:0003-3197
1940-1574